Notable examples include: (1) randomized trials of daratumumab in SLE and systemic sclerosis; (2) phase 2 studies of BCMA-targeted CAR-T cells in lupus nephritis; (3) trials combining rituximab with belimumab (BLISS-BELIEVE, NCT03312907); and (4) studies of next-generation anti-CD19 agents in various autoimmune conditions. Here, CD19 is linked to systemic lupus erythematosus.